Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Arcus Biosciences, Inc. (RCUS)

Pharmaceutical Preparations

https://www.arcusbio.com

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

3928 POINT EDEN WAY
HAYWARD, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/15/2018

Market Cap

1,439,068,850

Shares Outstanding

74,860,000

Weighted SO

74,855,565

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

CGEM --.--%

ANNX --.--%

GPCR --.--%

RLAY --.--%

DAWN --.--%

ABOS --.--%

XFOR --.--%

INZY --.--%

VECT --.--%

Beta

0.8940

Last Div

0.0000

Range

12.95-25.47

Chg

0.0100

Avg Vol

704437

Mkt Cap

1439068850

Exch

NYSE

Country

US

Phone

510 694 6200

DCF Diff

35.0235

DCF

-16.8935

Div Yield

0.0000

P/S

5.8262

EV Multiple

-5.6510

P/FV

2.2581

Div Yield %

0.0000

P/E

-5.7587

PEG

-0.1723

Payout

0.0000

Current Ratio

5.1357

Quick Ratio

5.1357

Cash Ratio

0.7839

DSO

48.7652

DIO

0.0000

Op Cycle

48.7652

DPO

421.1538

CCC

-372.3887

Gross Margin

0.9474

Op Margin

-1.1862

Pretax Margin

-0.9960

Net Margin

-1.0081

Eff Tax Rate

-0.0163

ROA

-0.2099

ROE

-0.4286

ROCE

-0.2969

NI/EBT

1.0122

EBT/EBIT

0.8396

EBIT/Rev

-1.1862

Debt Ratio

0.0093

D/E

0.0173

LT Debt/Cap

0.0000

Total Debt/Cap

0.0170

Int Coverage

0.0000

CF/Debt

-22.4545

Equity Multi

1.8677

Rec Turnover

7.4848

Pay Turnover

0.8667

Inv Turnover

0.0000

FA Turnover

5.0408

Asset Turnover

0.2083

OCF/Share

-2.7113

FCF/Share

-2.9308

Cash/Share

10.6367

OCF/Sales

-1.0000

FCF/OCF

1.0810

CF Coverage

-22.4545

ST Coverage

-22.4545

CapEx Coverage

-12.3500

Div&CapEx Cov

-12.3500

P/BV

2.2581

P/B

2.2581

P/S

5.8262

P/E

-5.7587

P/FCF

-5.3898

P/OCF

-5.8053

P/CF

-5.8053

PEG

-0.1723

P/S

5.8262

EV Multiple

-5.6510

P/FV

2.2581

DPS

0.0000

Latest Headlines (EST)

MarketWatch Jan 06, 05:58 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Jan 02, 12:26 The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts MarketWatch Dec 26, 12:18 20 favorite small-cap stocks for 2024 among Wall Street analysts Investing.com Nov 28, 04:05 5 Small-Cap Stocks to Buy as Russell 2000 Catches Up to Broader Market Rally Benzinga Nov 08, 15:00 What 9 Analyst Ratings Have To Say About Arcus Biosciences

Revenue Product Segmentation